
Opinion|Videos|January 8, 2025
Recent Safety and Efficacy Updates from the Investigator Initiated Study of Loncastuximab tesirine + Rituximab for the Treatment of R/R FL
Author(s)Juan Pablo Alderuccio, MD
A panelist discusses updates from from the phase 2 study of loncastuximab + rituximab from ASH 2024.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Discuss the updated results from the phase 2 study of loncastuximab + rituximab in R/R FL presented at ASH 2024
- What were the key efficacy results, what about the safety profile?
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5































